US FDA consults on generic drug user fee programme
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is inviting stakeholder feedback on its plans to develop a new user fee programme that would cover human generic drug applications (abbreviated new drug applications)1. Similar user fee programmes are already in place for human prescription drugs, brand animal drugs, generic animal drugs, medical devices and tobacco products.
You may also be interested in...
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: